Modality
Degrader
MOA
TYK2i
Target
Menin
Pathway
Apoptosis
CLLHNSCCPTSD
Development Pipeline
Preclinical
~May 2021
→ ~Aug 2022
Phase 1
Nov 2022
→ Mar 2027
Phase 1Current
NCT03694462
1,844 pts·CLL
2022-11→2027-03·Active
1,844 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-0711mo awayInterim· CLL
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Active
Catalysts
Interim
2027-03-07 · 11mo away
CLL
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03694462 | Phase 1 | CLL | Active | 1844 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin |